Revvity demonstrated strong performance in the fourth quarter, particularly in its Life Sciences reagents, software, and diagnostics segments. The company achieved impressive cash flow and continued strategic investments. However, challenges remain in the instrumentation business, and FX headwinds and market uncertainties present potential risks.

Company Guidance

During the fourth quarter 2024 earnings call, Revvity provided detailed guidance for 2025, highlighting expectations for a 3% to 5% organic growth rate, an improvement from the 1% organic growth experienced in 2024. The company anticipates adjusted operating margin expansion of 20 to 40 basis points from 28.3% in 2024, despite planning increased strategic internal investments. In Q4 2024, Revvity achieved 6% organic growth with over 30% adjusted operating margins, leading to an adjusted EPS of $1.42, surpassing expectations. For 2025, they expect total revenue to range between $2.8 billion and $2.85 billion, factoring in a 1.5% FX headwind and no acquisitions. Despite uncertainties, Revvity remains optimistic about continued strong performance, leveraging its significant operating leverage potential and differentiated growth prospects, especially as pharma and biotech spending normalizes.

Solid Fourth Quarter Performance

Revvity achieved 6% organic growth and over 30% adjusted operating margins in Q4 2024. Adjusted EPS was $1.42, exceeding expectations.

Life Sciences Reagents Growth

Life Sciences reagents demonstrated mid-single-digit growth for two consecutive quarters, indicating recovery in pharma biotech customer demand.

Strong Software Business Performance

Signals Software business grew over 30% in Q4 and achieved low-double-digit growth for the year, with a 106% net retention rate.

Diagnostics Segment Success

Diagnostics business achieved 4% organic growth for the year, with immunodiagnostics growing in the mid-single digits and reproductive health in the high single digits in Q4.

Cash Flow and Share Repurchase

Revvity generated $151 million in free cash flow in Q4, leading to $578 million for the year with a 96% conversion rate. The company repurchased $185 million in shares during Q4.

Strategic Partnerships and Innovations

Revvity expanded its partnership with Genomics England and announced a strategic partnership with Element Biosciences to commercialize a neonatal sequencing workflow.

---

Revvity (RVTY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RVTY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 06, 2025	2025 (Q1)	0.95 / -	0.98	―	―	―
Jan 31, 2025	2024 (Q4)	1.37 / 1.42	1.25	13.60% (+0.17)
Nov 04, 2024	2024 (Q3)	1.13 / 1.28	1.18	8.47% (+0.10)
Jul 29, 2024	2024 (Q2)	1.12 / 1.22	1.21	0.83% (+0.01)
Apr 29, 2024	2024 (Q1)	0.94 / 0.98	1.01	-2.97% (-0.03)
Feb 01, 2024	2023 (Q4)	1.17 / 1.25	1.7	-26.47% (-0.45)
Oct 30, 2023	2023 (Q3)	1.19 / 1.18	1.51	-21.85% (-0.33)
Aug 01, 2023	2023 (Q2)	1.19 / 1.21	2.32	-47.84% (-1.11)
May 11, 2023	2023 (Q1)	1.00 / 1.01	2.41	-58.09% (-1.40)
Feb 14, 2023	2022 (Q4)	1.64 / 1.70	2.56	-33.59% (-0.86)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

RVTY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 31, 2025	$126.84	$126.13	-0.56%
Nov 04, 2024	$120.97	$124.75	+3.12%
Jul 29, 2024	$115.01	$125.44	+9.07%
Apr 29, 2024	$101.33	$104.83	+3.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---